Aakash Desai/LinkedIn
Aug 31, 2025, 15:33
Aakash Desai: Exciting Insights at WCLC25
Aakash Desai, Associate Director, Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared on LinkedIn:
“Plans for the long weekend?
Prepare for exciting insights at WCLC25!
With groundbreaking data on oncogene-driven NSCLC, it’s going to be a conference to remember!
Here are my top picks:
- Ivonescimab + Placebo vs Chemo in EGFR+ NSCLC (HARMONi)
- First-Line Osimertinib + Chemo in EGFRm Advanced NSCLC (FLAURA2)
- Zidesamtinib in ROS1+ Advanced/Metastatic NSCLC
- And much more!
Looking forward to hearing the results and exploring new options for treatment!”
More posts featuring Aakash Desai.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 31, 2025, 15:39
Aug 31, 2025, 15:33
Aug 31, 2025, 15:28
Aug 31, 2025, 15:00
Aug 31, 2025, 14:48
Aug 31, 2025, 14:17
Aug 31, 2025, 13:57
Aug 31, 2025, 13:49